# Clinicopathology of adenocarcinoma originating from the anal gland with immunohistochemical expressions of GATA3 and TTF-1: a case report and literature review

**Authors:** Jianping Shi, Guofeng Li, Wen Tang, Bin Huang

PMC · DOI: 10.3389/fonc.2026.1673646 · 2026-03-12

## TL;DR

This case report describes a rare anal gland adenocarcinoma with specific protein markers and discusses its clinical and pathological features.

## Contribution

The report presents a rare case of ACAGGT with detailed clinicopathological and immunohistochemical findings.

## Key findings

- The tumor showed glandular and solid components with moderate TIL infiltration.
- Immunohistochemistry revealed positive GATA3 (90%) and TTF-1 (10%) expression.
- The tumor was microsatellite-stable with no common driver gene mutations detected.

## Abstract

Adenocarcinoma originating from the anal gland with immunohistochemical expression of GATA3 and TTF-1 (ACAGGT) is a rare entity. This report describes an 80-year-old female patient who detected a perianal mass without an obvious cause 10 years prior and presented to our hospital (Hangzhou, China) with local pain lasting 3 days. Preoperative B-ultrasound revealed a heterogeneous hypoechoic area in the right perianal region, adjacent to the subcutaneous tissue. Pelvic magnetic resonance imaging (MRI) with contrast enhancement showed an abscess on the right side of the anal canal. Under general anesthesia, the patient underwent lesion resection and anal sphincteroplasty. Pathological examination demonstrated that the tumor exhibited glandular and solid components with invasive growth. The stromal tumor-infiltrating lymphocyte (TIL) score was moderate (30%). Immunohistochemical staining suggested the following results: CK7 (+), GATA3 (90%, +), TTF-1 (10%, +), Vimentin (−), CK20 (−), and CDX-2 (−). The programmed death ligand 1 (PD-L1) combined positive score (CPS) was 5. Additionally, molecular testing failed to detect common driver gene mutations (e.g., KRAS/NRAS/BRAF), and the tumor was microsatellite-stable (MSS). The patient received postoperative radiotherapy. At 6 months of follow-up, metastasis to the right inguinal lymph nodes was identified.

## Linked entities

- **Genes:** KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845], NRAS (NRAS proto-oncogene, GTPase) [NCBI Gene 4893], BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673]
- **Proteins:** GATA3 (GATA binding protein 3), TTF1 (transcription termination factor 1), KRT7 (keratin 7), PRELID1 (PRELI domain containing 1), KRT20 (keratin 20), CDX2 (caudal type homeobox 2), CD274 (CD274 molecule)
- **Diseases:** adenocarcinoma (MONDO:0004970), abscess (MONDO:0005227)

## Full-text entities

- **Genes:** TTF1 (transcription termination factor 1) [NCBI Gene 7270] {aka TTF-1, TTF-I}, NRAS (NRAS proto-oncogene, GTPase) [NCBI Gene 4893] {aka ALPS4, CMNS, N-ras, NCMS, NRAS1, NS6}, CDX2 (caudal type homeobox 2) [NCBI Gene 1045] {aka CDX-3, CDX2/AS, CDX3}, KRT20 (keratin 20) [NCBI Gene 54474] {aka CD20, CK-20, CK20, K20, KRT21}, KRT7 (keratin 7) [NCBI Gene 3855] {aka CK7, K2C7, K7, SCL}, GATA3 (GATA binding protein 3) [NCBI Gene 2625] {aka HDR, HDRS}, VIM (vimentin) [NCBI Gene 7431], KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673] {aka B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}
- **Diseases:** perianal mass (MESH:C536030), tumor (MESH:D009369), Adenocarcinoma originating (MESH:D000230), abscess (MESH:D000038), metastasis (MESH:D009362), pain (MESH:D010146)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13019455/full.md

---
Source: https://tomesphere.com/paper/PMC13019455